

## Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 07 November 2023 Ref. No.: TCPCL/SEC/2023-24/00074

To,

The General Manager, Corporate relationship department, BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001

Scrip Code: 543321

The Manager, Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G,

Bandra-Kurla Complex, Bandra(E), Mumbai-400 051

Scrip Symbol: TATVA

Subject: Statement of Deviation / Variation in utilization of funds raised through QIP

Dear Sir/Madam,

Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Qualified Institutions Placement (QIP) for the quarter ended 30 September 2023 in the prescribed format. The same will be filed in XBRL mode separately.

We confirm that, as at 30 September 2023, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of QIP as mentioned in the objects stated in the Placement Document dated 29 August 2023.

Report issued by Monitoring agency report is being separately filed with the exchange.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

Kindly take the above information on your record.

Thanking You,

Yours Faithfully,

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi Company Secretary and Compliance Officer

M. No.: A37444

Encl.: As above



## **Tatva Chintan Pharma Chem Limited**

(CIN:L24232GJ1996PLC029894)



## Statement of Deviation/Variation in utilisation of funds raised:

Name of listed entity	Tatva Chintan Pharma Chem Limited
Mode of Fund Raising	Qualified Institutions Placement (QIP)
Description of mode of fund raising (Applicable	Not applicable
in case of others is selected)	
Date of Raising Funds	29-08-2023
Amount Raised (in Rs. million)	2000.00
Report filed for Quarter ended	30-09-2023
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CRISIL Ratings Limited
Is there a Deviation / Variation in use of funds	No
raised	
If yes, whether the same is pursuant to change in	Not Applicable
terms of a contract or objects, which was	
approved by the shareholders	
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Yours faithfully,

For Tatva Chintan Pharma Chem Limited

Chintan N. Shah

Chairman & Managing Director

DIN: 00183618

Place: Vadodara

Date: 07 November 2023